miRNA 221 improved left ventricular contractile function in MIRI mice. حسب Hongyu Li (1332669)

Mean case duration before and after intervention (t-statistic = -3.35, p <i>< </i>0.001), indicating a statistically significant difference in means. حسب Mohammad Bakhtiari (11838264)

General procedure for the synthesis of A and A-c1. حسب Xueqin lu (22250795)

Pretreatment of BM-MSCs improves the survival rate and incidence of DCS. حسب Chen Lu (135200)

Effect of BM-MSCs in improving DCS induced lung injury. حسب Chen Lu (135200)

Participants enrollment. حسب Chikondi Maluwa (20660522)

"…Attitude improved from 16.76 (93.1%) at baseline to 17.74 (98.6%) at the six-week mark. …"

KAP assessment scores (n = 422). حسب Chikondi Maluwa (20660522)

"…Attitude improved from 16.76 (93.1%) at baseline to 17.74 (98.6%) at the six-week mark. …"

EF-24 treatment significantly reduces cell viability in leukemia cell lines. حسب Ajeet P. Singh (22298432)

The Laboratory Animal Flow Diagram. حسب Xueqin lu (22250795)

"…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …"

¹H NMR spectra for kylo-0603. حسب Xueqin lu (22250795)

"…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …"

¹³C NMR spectra for Kylo-0603. حسب Xueqin lu (22250795)

"…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …"

The structures of T3 and Kylo-0603. حسب Xueqin lu (22250795)

"…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …"

Synthesis process of Kylo-0603. حسب Xueqin lu (22250795)

"…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …"

ESI-HRMS spectra for Kylo-0603. حسب Xueqin lu (22250795)

"…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …"

Effects of Kylo-0603 on the expression of related genes of the MASH mouse models. حسب Xueqin lu (22250795)

General procedure for the synthesis of B. حسب Xueqin lu (22250795)

Effects of Kylo-0603 on body weight, organ weight, and body fat content. حسب Xueqin lu (22250795)

The body weight and cholesterol levels of the mice were recorded before the administration of the drug. حسب Xueqin lu (22250795)

The trends of cholesterol metabolism-related gene expression in liver tissue. حسب Xueqin lu (22250795)

Kylo-0603’s EC50 & tissue levels. حسب Xueqin lu (22250795)